UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Microbiome & Probiotics Resources

Presentation Videos

Webinar: The potential of developing a new generation of microbiome therapies

With Thomas Dawson, Greg Hillebrand, Anindya Dasgupta and Liping Zhao

Cannabinoids and the Microbiome: How the Tone Impacts Clinical Trial Strategy

Najla Guthrie, President and CEO of KGK Science.

ProbioSatys®, Naturally Modulating the Appetite through the Microbiome

Grégory Lambert, CEO and Vice President of R&D, TargEDys

Claim Development and Substantiation: Legal and Regulatory Considerations

Jessica O’Connel, Partner at Covington & Burling LLP

Microbiome Therapeutics: Next Generation Prebiotic

Dale Pfost, CEO, MicroBiome Therapeutics

FMT-based discovery: from platform to product

Jos Seegers, Operations Manager, Caelus Health

Understanding the role of the gut microbiome in NAFLD

Lesley Hoyles, Associate Professor, Nottingham Trent University

Lysates vs Live Probiotics in Skin Care

Maya Ivanjesku, CSO, LaFlore Probiotic Skincare

Increasing plant protein digestion in an in vitro model

Koen Venema, Professor, Maastricht University

Advanced NGS solutions for microbiota research

Tingting Zhou, General Manager, Novogene

Identification and Therapeutic Application of Rationally Selected, Novel Components of the Human Skin Microbiome

Richard Gallo, Distinguished Professor and Founding Chair, Department of Dermatology

Ammonia Oxidising Bacteria: A Live Topical Therapeutic

Larry Weiss, Chief Medical Officer, AOBiome, LLC

From Integrated Multi-Omics to Causality in Microbiome Research

Paul Wilmes, Assistant Professor, Luxembourg Centre for Systems Biomedicine

Control of Appetite Through the Microbiome

Gregory Lambert, Chief Executive Officer, TargEDys

Mast Cells, Microbes and the Gut-Brain Axis

Niall Hyland, Lecturer in Pharmacology and Faculty APC Microbiome Institute, University College Cork, Ireland

Identifying Blood Microbiota: A Convenient Surrogate Biomarker of Gut Microbiota Dysbiosis

Benjamin Lelouvier, Chief Scientific Officer, Vaiomer

The Future of Gut Microbiome Analysis

Morten Isaksen, CEO, Bio-Me

Recent Developments in the Probiotic Research and Market

Maria Saarela, VTT Technical Research Centre of Finland

Gut feeling: function based microbiome research

Jan Majta, Bioinformatician, Microbiome Research, Ardigen

Mechanisms involved in the prevention of type I diabetes onset by Lactobacillus johnsonii N6.2

Graciela Lorca, Associate Professor, Department of Microbiology and Cell Science, University of Florida

Reports and Investor Spreadsheets

Translating Microbiome Futures

The Updated List Of Microbiome Companies And Investors

The Big List Of Prebiotics/Probiotics Companies And Investors

The Big List of Microbiome Companies and Investors

How to get Funding for your Human Microbiome Startup

Poster Presentations

Multiple approaches to innovate microbiome knowledge and rebalancing

Federica Carlomagno, Chiara Pesciaroli, ROELMI HPC

Translational pig model for microbiota management and its effects on intestinal health

Mark Bouwens et al

Oral Multispecies Probiotic Supplement to Colonise Vaginal Epithelium, Improve Bacterial Vaginosis Symptoms and Restore Vaginal Microbiota

Marco Boccarusso, Franco Vicariotto, Filippo Murina, Valerio Mezzasalma, Roelmi HPC srl

PhD project: Potential Probiotics from Gut Microbiota

Fang Huang, Industrial PhD-student Division of Biotechnology, KILU, Lund University & Aventure AB, Lund, Sweden

Computing Metabolic Routes in the Human Microbiome

Peter D. Karp, Markus Krummenacker, Mario Latendresse, SRI International

Flow Cytometry: A New Method to Enumerate Probiotic Spores

Dana Buckman, Michael Showell, John Gorsuch

Divergent meta-transcriptional response of the upper and lower jaw dental plaque biofilm after sucrose exposure

Bart Keijser, Michel Ossendrijver, Paulo de Boer, Lodewic Van Twillert, Mark Buijs, Roy Montijn

All-in-One Microbiome Analysis with OmicsBox

David Seide, Gabriele Nocchi, Jesús Gutiérrez, Robert Nica, Mariana Monteiro, Alejandro Rocamonde, Carlos Menor, Francisco Salavert, Stefan Götz

The Greenhouse Pharmacy: Cultivating plants for Cosmeceuticals

Wouter Verkerke, Sarina Veldman, Nieves Garcia, Filip van Noort

Presentation Slides

Leveraging the microbiome to address skin health and treat skin disease

Richard Andrews, President and CEO, Azitra Inc., USA

Time to consider Archaea as pharmabiotics for cardiovascular disease and more

Jean-François Brugère, Associate Professor, Université Clermont Auvergne, France

The BioCollective and Probiotic Development

Martha Carlin, CEO/Co-Founder, The BioCollective

The use of ‘live’ beneficial lactobacilli to treat skin conditions

Ingmar Claes, Chief Scientific Officer, Yun (Probiotherapy) NV, Belgium

Health Promoting Properties Encoded Within Fermented Food Microbiota

Paul Cotter, Head of Food Biosciences, Teagasc & Principal Investigator, APC Microbiome Institute

Scalp Microbiome – The next big shift in beauty

Marie Drago, Founder, Gallinée, UK

Insights from synthetic gut communities

Karoline Faust, Assistant Professor, Department of Microbiology and Immunology, KU Leuven, Belgium

Cannabinoids and the Microbiome: How the Tone Impacts Clinical Trial Strategy

Najla Guthrie, President/CEO, KGK Science

The collaborative efforts and research directions of European microbiome funding

Dirk Hadrich, Policy and Programme Officer, Health Research, Personalised Medicine, DG Research & Innovation, European Commission, Belgium

NIZO: Helping You Create Microbiome Modulators

Nils Hijlkema, Business Acceleration Team Leader Personal Care & Pharma

Understanding the role of the gut microbiome in nonalcoholic fatty liver disease

Lesley Hoyles, Associate Professor in Microbiology Nottingham Trent University, UK

Lysates vs Live Probiotic cultures in skincare – what are the benefits and differences?

Maya Ivanjesku, Chief Scientific Officer – LaFlore Probiotic Skincare, USA

The Asian gut microbiome, a new therapeutics discovery opportunity

Jonathan Krive, CEO, AsiaBiome

ProbioSatys, Naturally modulating the appetite via the microbiome

Grégory Lambert, CEO & Vice President of R&D, TargEDys SA, France

Postbiotics, why we believe they are probiotics 2.0

Aubrey Levitt, CEO, Postbiotics+

Mechanisms involved in the prevention of type I diabetes onset by Lactobacillus johnsonii N6.2

Graciela Lorca, Associate Professor, Department of Microbiology and Cell Science, University of Florida

Temporal Changes in the Facial Skin Microbiome – A One-Year Longitudinal Study in Normal Healthy Men and Women

Kausar Malik, Principal Research Scientist, Amway Corporation

MAPPAC (Microbiology Appendicitis Acuta) trial: Acute appendicitis and microbiota –etiology and effects of the antimicrobial treatment

Evelina Munukka, Research Director, Faculty of Medicine University of Turku, Finland

Claim Development and Substantiation: Legal and Regulatory Considerations

Jessica O’Connell, Partner, Covington & Burling LLP

Selecting Critical Attributes During Digestive Health Product Development

Noelle Patno, Nutrition Scientist, Digestive Health, Metagenics Inc.

Protecting Inventions in the Microbiome Space: Challenges and Strategies

Olga A. Partington, Associate, Sterne, Kessler, Goldstein & Fox

Postbiotic Metabolites: The New Frontier in Microbiome Science

Ross Pelton, Scientific Director, Essential Formulas

Collision of Industries: A Case Study of a GI Microbiome Modulator

Dale Pfost, CEO, MicroBiome Therapeutics

Shared responsibility for Industry, Regulators and Press: what to do to get the consumer correctly informed on probiotics?

Bruno Pot, Research Group of Industrial Microbiology and Food Biotechnology, Faculty of Sciences and Bioengineering Sciences, Vrije Universiteit Brussel, Belgium

Development of microbiome-derived products for cardiometabolic indications

Jos Seegers, Operations Manager, Caelus Health, The Netherlands

MicrobiomeSupport – a global initiative to coordinate microbiome research and innovation activities in the food system

Angela Sessitsch, Head of Competence Unit, AIT, Austrian Institute of Technology, Austria

Formulation, Scientific Substantiation and Labeling of Probiotics Products

Vandana Sharma, Principal Nutrition Scientist, Pharmavite

Transition of microbiota analysis from research tool to clinical utility

Finn Terje Hegge, CTO and Head of Operations, Genetic Analysis AS, Norway

Ingestion of probiotic Bacillus coagulans GBI-30, 6086 increases plant protein digestion in a dynamic, computer-controlled in vitro model of the small intestine (TIM-1)

Koen Venema, Professor of Gut Microbiology, Centre for Healthy Eating & Food Innovation, Maastricht University – campus Venlo, The Netherlands

MatriSys Bioscience – new developments

Mark Wilson, CEO, MatriSys Bioscience Inc